H.C. Wainwright analyst Ed Arce maintained a Hold rating on Galmed Pharmaceuticals (GLMD – Research Report) today. The company’s shares closed last Friday at $0.44.
According to TipRanks, Arce is a 4-star analyst with an average return of 10.0% and a 40.16% success rate. Arce covers the Healthcare sector, focusing on stocks such as Akebia Therapeutics, Assembly Biosciences, and Pliant Therapeutics.
The word on The Street in general, suggests a Hold analyst consensus rating for Galmed Pharmaceuticals with a $1.07 average price target, which is a 142.80% upside from current levels. In a report released today, Canaccord Genuity also downgraded the stock to a Hold with a $1.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $3.39 and a one-year low of $0.38. Currently, Galmed Pharmaceuticals has an average volume of 115.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It focuses on the development of the liver targeted stearoyl-coenzyme A desaturase-1 modulator Aramchol, novel, once-daily, oral therapy for the treatment of NASH for variable populations, as well as other liver associated disorders. The Aramchol is a synthetic conjugate of cholic acid, or a type of bile acid, and arachidic acid, or a type of saturated fatty acid, both of which, in their non-synthetic forms, are naturally occurring. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.
Read More on GLMD:
- Benchmark Co. Reaffirms Their Hold Rating on Western Digital (WDC)
- Needham Remains a Buy on Revolve Group (RVLV)
- Wall Street Analysts Are Neutral on Top Healthcare Picks
- RADA Schedules Second Quarter 2022 Results Release & Conference Call on Wednesday, August 17, 2022
- H.C. Wainwright Sticks to Its Buy Rating for Surface Oncology (SURF)
